A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle

The monoclonal antibody (mAb) against CD20 known as Rituxan is widely used to treat autoimmune diseases and lymphomas. However, further application of Rituxan faces challenges of high production cost, which limits its availability in developing countries. Here, we report a new approach for large pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ran, Tang, Chenjun, Guo, Huaizu, Tang, Bo, Hou, Sheng, Zhao, Lei, Wang, Jianwu, Ding, Fangrong, Zhao, Jianmin, Wang, Haiping, Chen, Zhongzhou, Dai, Yunping, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123398/
https://www.ncbi.nlm.nih.gov/pubmed/30181542
http://dx.doi.org/10.1038/s41598-018-31417-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123398/
https://www.ncbi.nlm.nih.gov/pubmed/30181542
http://dx.doi.org/10.1038/s41598-018-31417-2

Ejemplares similares